These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 8570945)
1. [New therapeutic prospects in Alzheimer disease]. Rouhart F Rev Med Interne; 1995; 16(11):860-3. PubMed ID: 8570945 [TBL] [Abstract][Full Text] [Related]
2. [Pharma-clinics. Drug of the month. Tacrine (Cognex)]. Scheen AJ Rev Med Liege; 1996 May; 51(5):379-81. PubMed ID: 8992561 [No Abstract] [Full Text] [Related]
3. [Alzheimer disease cannot be treated with Cognex]. Shafazand M Lakartidningen; 1996 Apr; 93(15):1406. PubMed ID: 8667714 [No Abstract] [Full Text] [Related]
4. [Tacrine and its derivatives in the therapy of Alzheimers disease]. Korábečný J; Spilovská K; Benek O; Musílek K; Soukup O; Kuča K Ceska Slov Farm; 2012 Oct; 61(5):210-21. PubMed ID: 23256654 [TBL] [Abstract][Full Text] [Related]
9. [More accurate diagnosis could identify patients suitable for tacrine therapy]. Andreasen N; Eriksson S; Karlsson I; Lindahl B; Lund M; Nordberg A; Wimo A; Winblad B; Astrand R Lakartidningen; 1996 Mar; 93(13):1200. PubMed ID: 8656831 [No Abstract] [Full Text] [Related]
10. Alzheimer's disease: the role of tacrine therapy. Jogerst G Iowa Med; 1995 Oct; 85(10):409-11. PubMed ID: 7591656 [No Abstract] [Full Text] [Related]
11. Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors. Koepp R; Miles SH JAMA; 1999 Jun 23-30; 281(24):2287-8. PubMed ID: 10386551 [No Abstract] [Full Text] [Related]
12. Pharmacoepidemiology of tacrine in Alzheimer's disease. Begaud B; Haramburu F; Miremont G Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():77-8. PubMed ID: 8899701 [No Abstract] [Full Text] [Related]
13. [Tacrine and "profitability"]. Nygaard HA Tidsskr Nor Laegeforen; 1997 Feb; 117(5):726. PubMed ID: 9102968 [No Abstract] [Full Text] [Related]
14. Tacrine in Alzheimer's disease. Levy R Lancet; 1989 Aug; 2(8658):329. PubMed ID: 2569126 [No Abstract] [Full Text] [Related]
16. [Tacrine against Alzheimer disease? Still uncertain for which patients may the treatment be beneficial]. Wallin A Lakartidningen; 1996 Jan; 93(1-2):22-4. PubMed ID: 8544526 [No Abstract] [Full Text] [Related]
17. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238 [TBL] [Abstract][Full Text] [Related]
18. [Patients must have right to test available therapy]. Lindahl C Lakartidningen; 1996 Mar; 93(13):1203-4. PubMed ID: 8656833 [No Abstract] [Full Text] [Related]
19. [Tetrahydroaminoacridine: a promising 'therapy' for Alzheimer's disease?]. Drukarch B; Stoof JC Ned Tijdschr Geneeskd; 1988 Oct; 132(40):1833-5. PubMed ID: 3185771 [No Abstract] [Full Text] [Related]
20. Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease. Wu WY; Dai YC; Li NG; Dong ZX; Gu T; Shi ZH; Xue X; Tang YP; Duan JA J Enzyme Inhib Med Chem; 2017 Dec; 32(1):572-587. PubMed ID: 28133981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]